SuppreMol and Protagen are collaborating on a Phase IIa study to identify therapy-related biomarkers in patients with systemic lupus erythematosus.

SM101, a recombinant, soluble, non-glycosylated version of Fcy receptor FcyRIIB, binds to auto-antibody / auto-antigen complexes and Fc receptors on the surface of immune cells to prevent the activation of an inflammation cascade.

In the study, Protagen’s biomarker portfolio will be used for the rapid identification of auto-antibody signatures in the serum of systemic lupus erythematosus patients.

Protagen’s UNIarray technology platform will identify the potential for a personalised systemic lupus erythematosus therapy concomitant to the clinical development of SM101.

In animal models, SM101 has shown efficacy by decreasing inflammation and immune reactions.

The collobaration and Phase IIa study are supported by the German Federal Ministry for Education and Research, as part of Leading Edge Cluster m4.